Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors
16 December 2019 - 11:00PM
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced
today that Robin L. Smith, MD, MBA has been appointed to its Board
of Directors.
Dr. Smith is a business leader, entrepreneur,
medical doctor, author and philanthropist who has held various
C-Suite and board positions in the biopharmaceutical industry. Her
experience includes significant contributions on numerous board
committees for public medical, digital and health care entities.
She currently serves on the boards of directors of Celularity,
Inc., a pioneer company focused on cancer and regenerative
medicine, Seelos Therapeutics, Inc. (NASDAQ: SEEL), Spiritus
Therapeutics, which she co-founded, the International Board of
Sanford Health, and is the Chairman, President and founder of the
Cura Foundation.
Dr. Smith has been recognized for her extensive
leadership in the biopharmaceutical industry winning an array of
industry awards and business recognitions. She received the
Regenerative Medicine Foundation (RMF) 2019 Stem Cell and
Regenerative Medicine Action Award for International Diplomacy in
2019, the 2018 HEALinc Future Health Humanitarian Award, the
Business Intelligence Group’s Woman of the Year Award in 2018 and
the 2018 Gold Stevie® Award for Woman of the Year (Government or
Non-Profit). In April 2016, Pope Francis awarded Dr. Smith Dame
Commander with Star Pontifical Equestrian Order of Saint Sylvester
Pope and Martyr and was awarded the Lifetime Achievement in
Healthcare and Science by The National Museum of Catholic Art and
Library. Dr. Smith is a 2016 recipient of the Women of Power and
Influence Awards and winner of the 2014 Brava Award.
She received her B.A. degree from Yale
University and her M.D. degree from the Yale School of Medicine.
Dr. Smith holds an M.B.A. degree from the Wharton School of
Business and completed the Stanford University Directors Program
and received an honorary Doctor of Science degree from Thomas
Jefferson Medical College
“Sorrento is an exciting clinical stage, antibody-centric,
biopharmaceutical company with unique assets and a commendable
commitment to developing new therapies for individuals with life
threatening illnesses. The company has an incredibly talented
management team and innovative scientists. I am honored to join
their board and appreciate the opportunity to work with the team
and other board members,” commented Dr. Smith.
Dr. Henry Ji, Chairman and CEO, commented, “We are very excited
to have Robin join our board. She brings deep medical, business
knowledge and diversity at a critical time for our company. I
believe Dr. Smith will be an invaluable addition to our board and
can be a great contributor to a bright future for Sorrento
Therapeutics.”
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to turn
malignant cancers into manageable and possibly curable diseases.
Sorrento's multimodal multipronged approach to fighting cancer is
made possible by its extensive immuno-oncology platforms, including
key assets such as fully human antibodies (“G-MAB™ library”),
antibody-drug conjugates (“ADC”) as well as CAR-T and oncolytic
virus (“Seprehvir®”).
Sorrento's commitment to life-enhancing therapies for cancer
patients is also demonstrated by its effort to advance a
first-in-class (TRPV1 agonist) RTX and ZTlido®. RTX is completing a
phase IB trial in terminal cancer patients. ZTlido® was approved by
US FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
Media and Investor Relations
Contact: Alexis Nahama, SVP Corporate Development
Telephone: 1.858.203.4120
Email: mediarelations@sorrentotherapeutics.com
ZTlido® and G-MAB™ are trademarks owned by Scilex
Pharmaceuticals Inc. and Sorrento, respectively.
Seprehvir®, is a registered trademark of Virttu Biologics
Limited, a wholly owned subsidiary of TNK Therapeutics, Inc. and
part of the group of companies owned by Sorrento Therapeutics,
Inc.
All other trademarks are the property of their respective
owners.
© 2019 Sorrento Therapeutics, Inc. All Rights
Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2024 to May 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From May 2023 to May 2024